The algorithm used in Insulet‘s (NSDQ:PODD) closed-loop insulin delivery system performed well in a 58-patient safety and feasibility study, according to a study published today in Diabetes Technology & Therapeutics. Insulet’s device, which is still in development, combines an insulin dosing algorithm, the OmniPod insulin patch pump and Dexcom‘s (NSDQ:DXCM) continuous glucose monitor into one system […]
DexCom Inc.
Dexcom takes on Abbott in head-to-head glucose monitoring trial
Updated to include a statement from Abbott. Dexcom (NSDQ:DXCM) touted data today from a head-to-head trial comparing its G5 mobile continuous glucose monitoring system with Abbott‘s (NYSE:ABT) recently-approved FreeStyle Libre Flash glucose monitoring system. The I-Hart study, which enrolled 40 people with Type I diabetes, found that Dexcom’s device reduced patients’ time spent in hypoglycemia by […]
WaveForm touts clinical trial data for continuous glucose monitor
WaveForm Technologies said today that it has finished four clinical trials of its continuous glucose monitoring system and that it expects to win CE Mark clearance for the device this year. The WaveForm CGM system is designed to be worn for 14 days and includes a sensor insertion tool, a small sensor wire, a polymer […]
Dexcom, UnitedHealth team up for wearable glucose management pilot program
Updated Jan. 17 to include confirmation of Fitbit’s participation. UnitedHealth (NYSE:UNH) and Dexcom (NSDQ:DXCM) are joining forces to launch an individualized glucose management pilot program to help people with Type II diabetes manage their condition in real-time using wearable tech. People using UnitedHealth’s Medicare Advantage plan are eligible to use Dexcom’s mobile continuous glucose monitoring system to […]
Dexcom posts cautious 2018 forecast despite Street-beating Q4, FY17 prelims
Dexcom (NSDQ:DXCM) shares fell today after the company issued conservative guidance for its expected revenue in 2018. The company also posted Street-beating preliminary results for its fourth quarter and full-year 2017 revenues. The company is facing competition in the new year after the FDA approval of Abbott‘s (NYSE:ABT) continuous glucose monitor, the FreeStyle Libre. But chief executive […]
Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor
Abbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitor is now available to Medicare patients, after the Centers for Medicare & Medicaid Services determined that the device can be classified as a therapeutic CGM. The FreeStyle Libre is designed to read glucose levels through a sensor worn on the back of a person’s upper […]
These 10 medtech companies care a lot about research
Among the world’s largest medtech companies, these 10 spent the largest portion of their budgets on research and development. So what have they produced? Every year, Medical Design & Outsourcing pulls financial regulatory filings and reaches out to major, companies in some cases to create a list of the 100 largest medical device companies in […]
Dexcom inks continuous glucose monitoring deal with UnitedHealth
Shares in Dexcom (NSDQ:DXCM) rose 4% today after the company announced a partnership with UnitedHealth (NYSE:UNH) to assess if data from a continuous glucose monitor can help people with Type II diabetes manage their condition in a cost-effective way. UnitedHealth is slated to use CGM data, as well as diet and exercise activity, in a study […]
Dexcom, Lilly ink deal to combine CGM into smart insulin delivery device
Dexcom (NSDQ:DXCM) said today that it inked a development deal with Eli Lilly (NYSE:LLY) to include its continuous glucose monitor in the insulin-maker’s connected delivery devices. The pair plans to start clinical trials by the end of this year, adding that they hope to position the combination of their technologies as a comprehensive solution for people with […]
Bigfoot Biomedical CEO hits back against CMS over data-sharing decision
Bigfoot Biomedical CEO Jeffrey Brewer has spoken out about a recent data-sharing decision made by CMS, saying that he plans to lobby Medicare to reverse its latest move. Earlier this year, CMS said it would begin covering the use of particular continuous glucose monitors for people with diabetes. But since that decision, the agency has […]